Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the full year 2024 financial results and business update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. I would now like to turn the conference over to Henry Wheeler, Vice President, Investor Relations and Communications. You may begin. Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release for our full year 2024 business update and financial results. We look forward to highlighting the progress made during the year to date, as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website. On slide two, before we start, I would like to remind you that we will be making forward-looking statements regarding the financial outlook in addition to the regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. On slide three, quickly cover today's agenda. After an introduction from Jonathan Dickinson, our CEO, Yanis Morel, COO, will then discuss our preclinical ANCET platform and ADC updates. He'll then hand over to Sonia Quarantino, our Chief Medical Officer, to cover the clinical updates on the Gutamab IPH6501 and IPH4502, who will then hand to Frederick to cover the financials, our CFO, who will then hand to Jonathan, who will then wrap and close. Thank you. Jonathan, over to you. Thank you, Henry. And good morning to our US participants and good afternoon in Europe. I'm happy to have the opportunity today to update you all on the latest develo...